| Purpose:This study aimed to investigate the effect of AO-I on immune inhibitory cytokines:TGF-β1、IL-17A、IL-10and IL-4secretion of MyD88+human ovarian cancer cells(SKOV-3), find out whether AO-I could attenuate secretion of these immune inhibitory cytokines or not in SKOV-3cells, as a result of reducing their immune inhibitory roles in EOC patients and activating the body’s immune response to tumor.Method:The same density SKOV-3cells were induced with different concentrations of AO-I (10μmol/L,50μmol/L and100μmol/L)、LPS (lmg/L) and does not dosing, respectively. And they were cultured for24hours, then we extracted the supernatant from the cells. Adopting enzyme-linked immunosorbent assay (ELISA) determined the concentration of TGF-β1, IL-17A, IL-10and IL-4in each group cell supernatant. SKOV-3cells groups induced with different concentrations of AO-I regarded as experimental groups, at the same time,SKOV-3cells group induced with LPS regarded as a positive control group, without drug-induced as a negative control group as well.Result: 1. SKOV-3cells can be able to autocrine TGF-β1, IL-17A, IL-10and IL-4, their concentration of (1196±18.81) pg/ml,(125.39±3.18) pg/ml,(48.88±1.54) pg/ml and (12.56±1.23) pg/ml, respectively.2. AO-I of low concentration (10μmol/L) has no significant inhibition to TGF-β1and IL-17A of SKOV-3cells secretion (P>0.05), however, concentration of both50μmol/L and100μmol/L can be able to attenuate the secretion of TGF-β1and IL-17A (P<0.05), and the greater AO-I concentration, more obvious inhibition of TGF-β1and IL-17A. LPS(1mg/L) can be capable of inducing the secretion of TGF-β1and IL-17A to increase (P<0.05)3. AO-I (10μmol/L,50μmol/L and100μumol/L) and LPS (lmg/L) have no effect on IL-10and IL-4of SKOV-3cells secretion, and comparison between the each group show no obvious difference (P>0.05)Conclusion:This experiment confirmed the SKOV-3cells can be able to autocrine TGF-β1, IL-17A, IL-10and IL-4. TGF-β1and IL-17A in the SKOV-3cells may also be secreted by My88+signaling pathway Mediating, however, IL-4and IL-10in the SKOV-3cells may not be secreted by My88+signaling pathway Mediating. within a certain range of concentrations, AO-I can attenuate SKOV-3cells to secrete immune suppression factors TGF-β1, BL-17A, IL-6,VEGF and so on, as a result of reducing their immune suppression roles in EOC patients and activating the body’s immune response to tumor. therefore, AO-I is expected to become a new effective anticancer drugs for ovarian cancer immunotherapy and can be generalize in clinical applications. |
PDF Full Text Request